Discontinued — last reported Q3 '23
TechnipFMC Equity Method Investments increased by 2.1% to $236.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.9%, from $253.40M to $236.00M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows a downward trend with a -8.4% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $324.00M | $295.60M | $292.40M | $292.20M | $301.90M | $315.30M | $325.00M | $339.10M | $267.10M | $280.00M | $274.40M | $275.30M | $277.30M | $286.30M | $244.50M | $253.40M | $234.70M | $231.90M | $231.10M | $236.00M |
| QoQ Change | — | -8.8% | -1.1% | -0.1% | +3.3% | +4.4% | +3.1% | +4.3% | -21.2% | +4.8% | -2.0% | +0.3% | +0.7% | +3.2% | -14.6% | +3.6% | -7.4% | -1.2% | -0.3% | +2.1% |
| YoY Change | — | — | — | — | -6.8% | +6.7% | +11.1% | +16.1% | -11.5% | -11.2% | -15.6% | -18.8% | +3.8% | +2.3% | -10.9% | -8.0% | -15.4% | -19.0% | -5.5% | -6.9% |